Pfizer Selects Sites for its Post-Merger Global R&D Network

Newly merged company will cut R&D staff by 15 percent, though timing is unclear.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet